Month: May 2021
Excerpt from the Press Release: WAYNE, Pa., May 4, 2021 /PRNewswire/ — In research to be shared during a plenary talk at the Society for Investigative Dermatology’s 2021 Virtual Meeting, data from investigators at the Tsai Lab at Moffitt Cancer Center, Sarin Lab at the Stanford University School of Medicine and NFlection Therapeutics demonstrate positive efficacy in preclinical models for the…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced initial data from its Phase 2 study showing that a single 50 µg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2…
Read More
Excerpt from the Press Release: TEL AVIV, Israel & SAN JOSE, Calif.–(BUSINESS WIRE)–RSIP Vision, an experienced leader in driving innovation for medical imaging through advanced AI and computer vision solutions, announced today a new prostate MRI-to-ultrasound registration tool. The tool’s fully automated, deep learning-based capabilities provide a robust method that utilizes a registered MRI scan…
Read More
Excerpt from the Article: Massachusetts General Hospital researchers have identified what’s known as a protein “signature” linked to severe health outcomes including death for people who contract COVID-19, according to an article published Tuesday in the Harvard Gazette. Researchers led by Dr. Marcia Goldberg, an MGH infectious disease expert, and Dr. Michael Filbin, an attending physician…
Read More
Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced the publication of data that further validate the potential of its mass cytometry technologies, CyTOF® and Imaging Mass Cytometry™ (IMC™), to provide new approaches to…
Read More
Excerpt from the Press Release: Researchers at Massachusetts General Hospital (MGH) and the Broad Institute of MIT and Harvard have identified the protein “signature” of severe COVID-19, which they describe in a new study published in Cell Reports Medicine. “We were interested in asking whether we could identify mechanisms that might be contributing to death in…
Read More
Excerpt from the Press Release: HAMILTON, ON and BOSTON, May 6, 2021 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that it has entered into a clinical trial collaboration with a subsidiary of Merck (known as MSD outside the U.S. and Canada) to evaluate Fusion’s lead candidate, [225Ac]-FPI-1434…
Read More
Excerpt from the Press Release: WALTHAM, Mass.–(BUSINESS WIRE)–Adagio Therapeutics, Inc., a biotechnology company developing highly differentiated antibodies to broadly neutralize coronaviruses, today announced that the first patient has been treated in the company’s Phase 2/3 pivotal trial evaluating ADG20 for the prevention of COVID-19, known as the EVADE trial. Trial initiation is supported bypositive preliminary…
Read More
Excerpt from the Press Release: ZUG, Switzerland, CAMBRIDGE, Mass., and SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) — CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, and Nkarta, Inc. (NASDAQ: NKTX), a biopharmaceutical company developing engineered NK cell therapies to treat cancer, today announced a…
Read More Excerpt from the Press Release: BOSTON, April 29, 2021 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that the first patient has been dosed in the Phase 3 MORNINGSKY trial, a global multicenter trial evaluating AT-527 in mild or moderate COVID-19 patients in an outpatient setting. The trial, which…
Read More- « Previous
- 1
- 2
- 3
- 4
- Next »